Elucidation of immunoabnormality on plumonary mucosal immune system of streptozotocin-induced type I diabetes mice model and analysis of improving effect of Hachimigan

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08930
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General internal medicine(including psychosomatic medicine)
• Research Institution: Kitasato University
• Principal Investigator: Kiyohara Hiroaki 北里大学, 感染制御科学府, 教授 (70161601)
• Co-Investigator(Kenkyū-buntansha): 永井 隆之 北里大学, 感染制御科学府, 准教授 (00172487) ; 丸山 弘子 北里大学, 医療衛生学部, 准教授 (50129269)
• Co-Investigator(Renkei-kenkyūsha): OIKAWA Tetsuro 北里大学, 東洋医学総合研究所, 副所長 (10370165)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 八味丸 / 糖尿病 / 肺粘膜免疫系

Outline of Final Research Achievements

It is well known that diabetes patients tend to receive pulmonary infectious diseases, however effective preventive or therapeutic medical strategy have not been developed. By the present study using transcriptome analyses, it was strongly indicated that expression of E/P-selectin recruitements of T and B lymphocytes decreased in lung tissues in streptozotocin-induced type I diabete mice model. Administration to the model mice improved reduced expression of P-selectin, resulting increment of T lymphocyte recruitement in lung tissues in addition to up-regulation of complement factor, C1q. Although expression of angiotensin II receptor (AT1a) in the lung tissues of the model mice significantly increased by administration of Hachimigan, this administration also improved pneumonia induced by pulmonary inoculation of poly(I:C).

Free Research Field

漢方免疫薬理学